KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial.

Vikas Ostwal, Manali Parulekar, Deepali Naughane, Anant Ramaswamy, Tejashree Garkal, George John, Sarika Mandavkar, Prabhat Bhargava, Anuj Gupta, Akhil Kapoor, Pradnya Joshi, Omshree Shetty, Sujay Srinivas, Sadhana Kannan, Deepali Chaugule, Poonam Jadhav, Amit Joshi, Jaya Ghosh, Vanita Noronha, Nandini Menon, Kumar Prabhash, Mahesh Khandare, Sucheta More, Supriya Gaud, Shripad Banavali, Sudeep Gupta

JCO Glob Oncol 12(3) e2500386

PMID41812092
PMCID-
DOI10.1200/GO-25-00386
发表日期2026-03-11
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: Carica papaya leaf extract (CPLE) is known to increase platelet counts (PCs) in certain infections. METHODS: Patients were randomly assigned in a 2:1 ratio to the CPLE or placebo arm and continued treatment until the PC improved to 75,000 × 109/L or above, a platelet transfusion was required, or upto D+10. The primary outcome was to evaluate whether CPLE improves PC faster compared with placebo in a significant proportion of patients with a modified intention-to-treat protocol. RESULTS: Between March 2020 and October 2024, 219 patients were randomly assigned, of whom 198 patients (CPLE arm: 129; placebo arm: 69) were analyzed for outcomes. The primary end point with modified intention-to-treat analysis showed a statistically significant increase in PC to ≥75,000 × 109/L in a greater proportion of patients by D+4 compared with placebo (59% v 44%; P = .042). The primary outcome of increasing PC >75,000 × 109/L at D+4 was significantly improved by CPLE (83/129, 64% v 33/69, 48%; P = .034) compared with placebo as per protocol analysis. There was no grade 3 or grade 4 treatment-related adverse events associated with CPLE. About 43% of patients in the placebo arm versus 25% of patients in the CPLE arm needed dose reductions or delays in their subsequent chemotherapy treatment for patients with grade 2 chemotherapy-induced thrombocytopenia (CIT) at the baseline (P 0.033) and not significant in grade 3 CIT. CONCLUSION: CPLE is a potential therapeutic intervention to improve CIT faster and to a greater extent than placebo in this phase III randomized trial without any safety concerns. It could be potentially used as a secondary prophylaxis to maintain the chemotherapy intensity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。